Ronald Asbury Andrews
Ronald Asbury Andrews's purchase track record
Ronald Asbury Andrews has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2022 | IMDX | $38K | -55.5% | -53.1% | -3.9% |
| 3/16/2022 | IMDX | $64K | -15.0% | -24.2% | -9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precipio Management Signals Growth, Institutions Take Interest. Precipio’s leadership outlined ambitious plans for future growth, drawing attention from institutional investors. The company’s strategy includes expanding its product line and entering new markets. Institutional involvement suggests confidence in the company’s direction. The move may influence investor sentiment and the stock’s short‑term activity.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
Transaction History
| CNSY | ▲ Buy | Option Exercise | 921 | $0 | 10/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 922 | $0 | 7/1/2026 | View on chart |
| PRPO | ▲ Buy | Grant | 568 | $10K | 10/15/2025 | View on chart |
| PRPO | ▲ Buy | Grant | 676 | $10K | 7/16/2025 | View on chart |
| PRPO | ▲ Buy | Grant | 1,785 | $10K | 4/15/2025 | View on chart |
| PRPO | ▲ Buy | Grant | 1,639 | $10K | 1/15/2025 | View on chart |
| PRPO | ▲ Buy | Grant | 1,510 | $10K | 10/15/2024 | View on chart |
| PRPO | ▲ Buy | Grant | 2,157 | $10K | 7/15/2024 | View on chart |
| PRPO | ▲ Buy | Grant | 3,153 | $21K | 4/15/2024 | View on chart |
| PRPO | ▲ Buy | Grant | 4,005 | — | 10/24/2023 | View on chart |
| PRPO | ▲ Buy | Grant | 6,060 | — | 9/12/2023 | View on chart |
| IMDX | ▲ Buy | Option Exercise | 250,000 | $0 | 12/1/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 40,000 | $38K | 8/16/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 50,000 | $64K | 3/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.